Related Experiment Videos
Axonal protection using flecainide in experimental autoimmune encephalomyelitis.
David A Bechtold1, Raju Kapoor, Kenneth J Smith
1Department of Neuroimmunology, King's College, London, United Kingdom.
Annals of Neurology
|May 4, 2004
Summary
Flecainide, a sodium channel blocker, protected axons from degeneration in an experimental model of multiple sclerosis (MS). This suggests potential new therapies for MS and other neuroinflammatory disorders.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Axonal degeneration is a primary cause of irreversible neurological deficits in multiple sclerosis (MS).
- Current MS therapies do not effectively protect axons.
- There is a critical need for novel therapeutic strategies targeting axonal protection in MS.
Purpose of the Study:
- To investigate the efficacy of flecainide, a sodium channel blocker, in preventing axonal degeneration.
- To evaluate flecainide's neuroprotective potential in a rat model of MS, chronic relapsing experimental autoimmune encephalomyelitis (CR-EAE).
Main Methods:
- Rats with CR-EAE were administered flecainide or a vehicle control.
- Treatment was initiated either 3 days before or 7 days post-inoculation (dpi).
- Axon survival was quantified using morphometric analysis of neurofilament-labeled axons in the spinal cord.
Main Results:
- Flecainide treatment significantly increased axon survival in CR-EAE rats compared to controls.
- Axon survival rates were 83% and 98% in flecainide-treated groups versus 62% in the control group.
- Both early and delayed treatment regimens demonstrated significant neuroprotection.
Conclusions:
- Flecainide demonstrates significant efficacy in reducing axonal degeneration in an experimental model of MS.
- Sodium channel blockers like flecainide represent a promising therapeutic avenue for axonal protection.
- These findings may translate to novel treatments for MS and other neuroinflammatory conditions.